Winner F A Plus Injection

Adult dosage

Determine dosage and infusion rate according to the patient's fat removal ability, nitrogen and glucose metabolic capacity, and nutritional needs. The dosage and bag size depend on the patient's condition and weight. - For patients with normal nutritional status or mild metabolic stress: Nitrogen as 0.10-0.15 g/kg/day (as amino acids, 0.6-0.9 g/kg) - For patients under moderate to severe metabolic stress, regardless of nutritional imbalance: Nitrogen as 0.15-0.25 g/kg/day (as amino acids, 0.9-1.6 g/kg) In very special cases (e.g., burns or significant anabolic states), nitrogen amounts may be higher. Dosage This medication at a rate of 13-33 mL/kg/day corresponds to nitrogen 0.137-0.347 g/kg and total calories 11.986-30.426 kcal/kg (non-protein calories 8.684-22.044 kcal/kg). This generally meets the requirements of most patients. For obese patients, the dosage should be based on the estimated normal body weight. Infusion rate The infusion rate should not exceed 1.5 mL/kg/hour (equivalent to dextrose 0.125 g/kg, amino acids 0.095 g/kg, fats 0.053 g/kg). The recommended duration of administration is ideally over 14-24 hours. Maximum daily dosage The maximum daily dosage varies based on the patient's clinical condition and may change daily. The recommended maximum daily dosage is 33 mL/kg. The recommended maximum daily dosage of 33 mL/kg provides nitrogen 0.347 g/kg (as amino acids 2.096 g/kg), dextrose 2.746 g/kg, fats 1.168 g/kg, and total calories 30.426 kcal/kg (equivalent to non-protein calories 22.044 kcal/kg). Administration method Administer via central venous intravenous drip. Pediatric patients Use in pediatric patients is not recommended.

Children's dosage

Use in pediatric patients is not recommended.

This drug must be used according to the doctor's instructions, and if allergic reactions such as fever, chills, rash, or difficulty breathing occur during use, administration must be stopped immediately. Moreover, using this medicine with certain calcium-containing intravenous preparations or ceftriaxone can result in precipitation, so they should not be administered simultaneously using the same infusion device. It should be used cautiously in premature or low-birth-weight infants, as administration in premature infants with serious respiratory conditions has been reported to pose a risk of death. Patients with allergies to fish, eggs, soybeans, peanuts, or who have severe hyperlipidemia, liver dysfunction, blood coagulation disorders, severe kidney failure, acute shock, or uncontrolled hyperglycemia should not use this medication. Patients with renal failure, diabetes, liver dysfunction, sepsis, or any condition affecting fat metabolism should be cautious during administration. This medicine can cause side effects like fever, generalized edema, nausea, constipation, dizziness, delirium, nausea, vomiting, chills, sweating, increased body temperature, and hyperglycemia; serious conditions like lipid overload syndrome may occur, so administration should be discontinued if symptoms appear. If an excess of amino acids or dextrose is administered, side effects such as nausea, vomiting, or hyperglycemia may occur, so recommended doses and rates should be strictly adhered to. During the initial administration, the patient's condition should be closely monitored, and administration should start after electrolyte and fluid balance has been improved. The risk of infection is higher when administered via central venous access, so aseptic procedures must be strictly followed, and regular monitoring of blood lipid levels and other clinical indicators should be conducted to detect any abnormal signs early. If this medication is used for an extended period, there should be management of nutritional status considering increased excretion of trace elements, and it should not be administered simultaneously with blood. In patients with renal failure, phosphate and potassium intake should be controlled to prevent hyperphosphatemia and hyperkalemia, and electrolyte dosages should be adjusted based on the patient’s condition. In patients with poor nutritional status, fluid shifts can lead to pulmonary edema or heart failure, making careful observation and adjustment necessary during administration. The safety in pregnant and nursing women has not been established, thus it should only be used when the therapeutic benefits outweigh the potential risks. In cases of overdose, the infusion rate should be slowed or stopped, and appropriate treatments such as insulin administration or hemodialysis should be implemented if necessary. This medicine should be stored at 1-30°C, kept sealed to prevent air exposure, and used immediately after mixing; if not, it should be used within 24 hours at 2-8°C.

Serious side effects

Anaphylactic reaction (fever, chills, rash, difficulty breathing), intravascular fat accumulation, lipid overload syndrome (hyperlipidemia, fever, jaundice, coma, etc.)

Mild side effects

• Fever
• generalized edema
• nausea
• constipation
• decreased blood counts
• dizziness
• delirium
• nausea
• vomiting
• chills

This medicine should be stored in a sealed container to protect it from air exposure, ideally kept at room temperature between 1°C and 30°C. Storing it this way maintains its efficacy and prevents deterioration.

Appearance

This medicine consists of three compartments separated by an interior white and external packaging, with oxygen absorber pouches in between. Each compartment contains a dextrose solution, an amino acid and electrolyte solution, and

Package unit

1085mL (A solution 215mL, B solution 689mL, C solution 181mL) / bag, 1090mL (A solution 216mL, B solution 692mL, C solution 182mL) / bag, 1438mL (A solution 285mL, B solution 913mL, C solution 240mL) / bag, 1820mL (A solution 360mL, B solution 1156mL, C solution 304mL) / bag